December 31, 2019
Authored and Edited by Nicholas J. Doyle; Samhitha Muralidhar Medatia; Elizabeth D. Ferrill
In Chamberlain Group, Inc. v. One World Technologies, Inc., No. 2018-2112 (Fed. Cir. Dec. 17, 2019), the Court addressed whether the Patent Trial and Appeal Board acted appropriately in disregarding an argument raised for the first time at the oral hearing.
In disputing the proper construction of a claim term in an inter partes review, the petitioner, One World, advanced a new argument for its claim construction for the first time in its reply brief. The patent owner, Chamberlain, responded to that argument at its first possible opportunity: the oral hearing. In the final written decision, the Board held that Chamberlain had waived its argument because the argument was not briefed and, per the Trial Practice Guide, new evidence or arguments may not be presented at the oral hearing.
The Federal Circuit disagreed. The Federal Circuit viewed Chamberlain’s argument as a clarification of arguments made in its response brief because the arguments were responsive to One World’s reply and tracked the arguments in its response. Because this clarification did not amount to a new issue or argument, the Federal Circuit determined that Chamberlain had not waived the argument.
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.